NASDAQ:CYAD
Delisted

Celyad Sa Stock News

etoro logo Buy CYAD
*Your capital is at risk
$0.470
+0 (+0%)
At Close: Aug 17, 2023
Top Ranked Momentum Stocks to Buy for April 20th
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 20th

Stocks To Watch: OPEC Goes Virtual

01:04pm, Saturday, 04'th Apr 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th

What Makes Celyad SA (CYAD) a New Buy Stock

04:00pm, Tuesday, 31'st Mar 2020
Celyad SA (CYAD) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Celyad SA (EBR:CYAD) shareholders will doubtless be very grateful to see the share price up 43% in the last week. But...

Celyad (CYAD) Received its Third Buy in a Row

08:06pm, Wednesday, 25'th Mar 2020
After H.C. Wainwright and William Blair gave Celyad (NASDAQ: CYAD) a Buy rating last month, the company received another Buy, this time from JonesTrading.

Celyad (CYAD) Received its Third Buy in a Row

08:05pm, Wednesday, 25'th Mar 2020
After H.C. Wainwright and William Blair gave Celyad (NASDAQ: CYAD) a Buy rating last month, the company received another Buy,
William Blair analyst Raju Prasad maintained a Buy rating on Celyad (CYAD) today. The company's shares closed last Monday at $7.25. According to
William Blair analyst Raju Prasad maintained a Buy rating on Celyad (CYAD – Research Report) today. The company’s shares closed
H.C. Wainwright analyst Edward White maintained a Buy rating on Celyad (CYAD) today and set a price target of $37.00. The company's shares closed last
H.C. Wainwright analyst Edward White maintained a Buy rating on Celyad ( CYAD – Research Report ) today and set a price target of $37.00 . The company’s shares closed last Monday at $7.25. Accordi

Celyad SA to Host Earnings Call

03:00pm, Wednesday, 25'th Mar 2020
NEW YORK, NY / ACCESSWIRE / March 25, 2020 / Celyad SA (NASDAQ:CYAD) will be discussing their earnings results in their 2019 Second Half Earnings call to be held on March 25, 2020 at 1:00 PM Eastern T
First patient successfully dosed in expansion cohort of autologous CYAD-01 THINK trial  for  patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) and.
MONT-SAINT-GUIBERT, Belgium, March 12, 2020 -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE